An expert discusses how the positive efficacy findings from the phase 3 RESPONSE trial, showing high rates of hematocrit control and spleen response with ruxolitinib vs standard therapy in hydroxyurea ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback